Cicor Technologies (CICN) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
14 Apr, 2026Executive summary
Achieved strong order intake in Q1 2026, especially in Aerospace & Defence, with new customer wins including Kongsberg.
Net sales rose 22.6% year-over-year to CHF 160.7 million, driven by M&A growth despite organic decline and FX headwinds.
Order backlog and book-to-bill ratio of 1.22 provide solid revenue visibility for upcoming quarters.
Financial highlights
Q1 2026 net sales: CHF 160.7 million, up from CHF 131.1 million in Q1 2025.
Order intake reached CHF 196.4 million, up from CHF 125.8 million year-over-year.
Organic sales declined by 6%, while M&A contributed 33.4% growth; currency impact was -4.8%.
Outlook and guidance
Expects organic growth to return in 2026, with momentum building in the second half as supply chain constraints ease.
2026 sales guidance: CHF 700–750 million; adjusted EBITDA: CHF 70–80 million, assuming stable geopolitical conditions.
Active M&A pipeline to support long-term profitable growth.
Latest events from Cicor Technologies
- Revenue up 19% to CHF 334.1m, order intake up 39.8%, integration boosts outlook.CICN
Q2 2026 - Achieved 28.2% sales growth in 2025 and targets CHF 700-750 million sales for 2026.CICN
Investor presentation - 2025 sales surged 28.2% to CHF 616.5 million, fueled by acquisitions and sector growth.CICN
Investor presentation - Revenue up 28% to CHF 616.5–660m, five acquisitions, and strong 2026 outlook.CICN
Q4 2025 - Transformational acquisition forms the largest global HMLV EMS provider, driving growth and synergies.CICN
M&A Announcement (Media) - Sales up 21.4% year-over-year, guidance raised on strong M&A and Q2 organic growth.CICN
H1 2025 - Ambitious 2028 targets CHF 1B+ revenue via M&A, innovation, and operational excellence.CICN
CMD 2024 Presentation - Net profit rose 53.9% as acquisitions drove record sales and upgraded guidance.CICN
H1 2024 - Record sales, profit, and cash flow in 2024 set the stage for continued growth in 2025.CICN
H2 2024